Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.

[1]  I. Hirsch,et al.  The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies , 2017, Current medical research and opinion.

[2]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[3]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[4]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[5]  E. Bel,et al.  Improving the diagnosis of eosinophilic asthma , 2016, Expert review of respiratory medicine.

[6]  K. Ranade,et al.  Reductions in eosinophil biomarkers by benralizumab in patients with asthma. , 2016, Respiratory Medicine.

[7]  David Price,et al.  Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice , 2016, Journal of asthma and allergy.

[8]  D. A. Korevaar,et al.  Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes , 2015, European Respiratory Journal.

[9]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[10]  Jérémie F. Cohen,et al.  Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. , 2015, The Lancet. Respiratory medicine.

[11]  S. Fowler,et al.  High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. , 2015, The Journal of allergy and clinical immunology.

[12]  P. Paggiaro,et al.  Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study , 2015, BMJ Open.

[13]  R. Lutter,et al.  External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma , 2014, Thorax.

[14]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[15]  Á. Cruz,et al.  Risk factors for death in patients with severe asthma* , 2014, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[16]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[17]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[18]  E. Bleecker,et al.  Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. , 2013, The Journal of allergy and clinical immunology.

[19]  A. Bush,et al.  Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma , 2013, Allergy.

[20]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[21]  Teresa To,et al.  Global asthma prevalence in adults: findings from the cross-sectional world health survey , 2012, BMC Public Health.

[22]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.

[23]  I. Pavord,et al.  Mepolizumab in refractory eosinophilic asthma , 2010, Thorax.

[24]  L. Lynd,et al.  Direct health care costs associated with asthma in British Columbia. , 2010, Canadian respiratory journal.

[25]  S. Wenzel,et al.  Tissue and BAL based biomarkers in asthma. , 2007, Immunology and allergy clinics of North America.

[26]  S. Peters,et al.  Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. , 2006, Respiratory medicine.

[27]  P. O'Byrne,et al.  Predictors of loss of asthma control induced by corticosteroid withdrawal. , 2006, Canadian respiratory journal.

[28]  E. Juniper,et al.  Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older , 2005, Health and quality of life outcomes.

[29]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[30]  Robert Tibshirani,et al.  The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd Edition , 2001, Springer Series in Statistics.

[31]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .